Cargando…
Immunotherapy through the Lens of Non-Small Cell Lung Cancer
SIMPLE SUMMARY: The landscape of non-small cell lung cancer has changed dramatically over the past decade. This is largely due to the introduction of immunotherapy, and in particular, immune checkpoint blockade inhibitors. Anti-PD-1 immunotherapy is now standard treatment for patients with non-small...
Autores principales: | Stanley, Robyn, Flanagan, Saoirse, Reilly, David O’, Kearney, Ella, Naidoo, Jarushka, Dowling, Catríona M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252117/ https://www.ncbi.nlm.nih.gov/pubmed/37296957 http://dx.doi.org/10.3390/cancers15112996 |
Ejemplares similares
-
Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023) -
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021) -
Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022) -
From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)